Keywords targeted therapy cell state monocytic progenitor Introduction In recent years, initial remission rates for elderly patients with acute myeloid leukemia (AML) have seen improvement due to the combination therapy of the BCL2 inhibitor venetoclax (ven) with hypomethylating agents azacitidine (aza) and decitabine.1,2 However, drug resistance and disease relapse continue to be major hurdles in the long-term management and overall survival of patients with AML due to the heterogeneity of...
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Andy Kaempf
Prognostic impact of chronic lymphocytic leukemia comorbidity index in a young population: a real-world evidence study of a national gulf region cohort | BMC Cancer | Full Text
References Hallek M, Eichhorst B, Catovsky D. Chronic lymphocytic leukemia. Cham: Springer International Publishing; 2019. Google Scholar Pflug N, Bahlo J, Shanafelt TD, et al. Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. Blood. 2014;124:49–62. https://doi.org/10.1182/blood-2014-02-556399. Article CAS PubMed PubMed Central Google Scholar Molica S, Giannarelli D, Visentin A, et al.
CDK 4/6 inhibitors are associated with a high incidence of thrombotic events in women with breast cancer in real‐world practice
ORIGINAL ARTICLE Malinda T. West Corresponding Author westmal@ohsu.edu orcid.org/0000-0002-2773-6320 OHSU Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA Correspondence Malinda T. West, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA.
Everolimus Plus Exemestane Treatment in Patients with Metastatic Hormone Receptor‐Positive Breast Cancer Previously Treated with CDK4/6 Inhibitor Therapy
Disclosures of potential conflicts of interest may be found at the end of this article. No part of this article may be reproduced, stored, or transmitted in any form or for any means without the prior permission in writing from the copyright holder. For information on purchasing reprints contact commercialreprints@wiley.com. For permission information contact permissions@wiley.com.
Dual inhibition of JAK1/2 kinases and BCL2: a promising therapeutic strategy for acute myeloid leukemia
JWT receives research support from Agios, Aptose, Array, AstraZeneca, Constellation, Genentech, Gilead, Incyte, Janssen, Seattle Genetics, Syros, Takeda; JWT is a co-founder of Leap Oncology. BJD serves on the advisory boards for Gilead, Aptose, and Blueprint Medicines. BJD is principal investigator or coinvestigator on Novartis and BMS clinical trials. His institution, OHSU, has contracts with these companies to pay for patient costs, nurse and data manager salaries, and institutional overhead.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Andy
Contact Andy, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack